These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 198301)

  • 1. Immunogenic quality of foot-and-mouth disease virus.
    Strobbe R
    Dev Biol Stand; 1976; 35():311-21. PubMed ID: 198301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evalutation of some methods of assay of foot-and-mouth disease antigen for vaccines.
    Garland AJ; Mowat GN; Fletton B
    Dev Biol Stand; 1976; 35():323-32. PubMed ID: 198302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Routine physico-chemical testing of concentrated virulent and inactivated foot-and-mouth disease virus antigens].
    Adamowicz P; Guerche J; Galampoix J; Prunet P
    Dev Biol Stand; 1976; 35():301-10. PubMed ID: 198300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Various physical and chemical properties of the 73s unit of the foot-and-mouth disease virus].
    Liebermann HT; Meissner J; Schulze P; Thalmann G
    Arch Exp Veterinarmed; 1976; 30(6):813-21. PubMed ID: 190967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine titration of foot-and-mouth disease virus suspensions by analytical ultracentrifugation 2nd communication: sedimentation equilibrium method.
    Strobbe R; Lacroix C; Charlier G; Debecq J
    Arch Exp Veterinarmed; 1977; 31(3):397-404. PubMed ID: 200195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Physical chemical measurement of 140S particles of the foot-and-mouth disease virus].
    Fayet MT; Fargeaud D; Louisot P; Stellmann C; Roumiantzeff M
    Ann Inst Pasteur (Paris); 1971 Jul; 121(1):107-18. PubMed ID: 4329751
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of the immunogenic potencies of purified inactivated foot-and-mouth disease virus particles with variable amounts of VP1 protein (author's transl)].
    Bernard S; Grosclaude J; Adamowicz P; Guerche J
    Ann Rech Vet; 1977; 8(1):79-94. PubMed ID: 195512
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenging settled opinions in classic foot-and-mouth disease vaccine preparation.
    Barteling SJ; Anemaet DA
    Dev Biol Stand; 1987; 66():531-8. PubMed ID: 3034709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative trial of the immunogenic properties of commercial foot-and-mouth virus strains].
    Tekerlekov P; Nikolova E
    Vet Med Nauki; 1981; 18(1):19-26. PubMed ID: 6272473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the correct quantitative relations of antigen components in mono-, bi- and trivalent foot-and-mouth disease vaccine preparations.
    Sólyom F; Czelleng F
    Dev Biol Stand; 1976; 35():289-94. PubMed ID: 198297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditions for proper formaldehyde inactivation of foot and mouse disease alhydrogel vaccines.
    Barteling SJ
    Dev Biol Stand; 1985; 60():323-9. PubMed ID: 2995172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of intact 146S foot-and-mouth disease antigen for vaccine production by a double antibody sandwich ELISA using monoclonal antibodies.
    Van Maanen C; Terpstra C
    Biologicals; 1990 Oct; 18(4):315-9. PubMed ID: 2178351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological behaviour & antigenicity of mouse passaged & formol inactivated foot & mouth disease virus type Asia-1 in guineapigs.
    Saraswat KC; Sharma KN; Mehrotra PN
    Indian J Exp Biol; 1980 Mar; 18(3):275-8. PubMed ID: 6248457
    [No Abstract]   [Full Text] [Related]  

  • 14. [Binary ethyleneimine as an inactivator of the foot-and-mouth disease virus].
    Tekerlekov P; Veleva E
    Vet Med Nauki; 1985; 22(3):3-8. PubMed ID: 2986348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antigenic structure of the foot-and-mouth-disease virus. I. Synthesis of protective peptides from the major immunogenic region of VP1 protein of foot-and-mouth virus type O1K].
    Surovoĭ AIu; Vol'pina OM; Snetkova EV; Volkova TD; Ivanov VT
    Bioorg Khim; 1988 Oct; 14(10):1352-62. PubMed ID: 2852937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine titration of foot and mouth disease virus suspensions by analytical ultracentrifugation. 1: Sedimentation method.
    Strobbe R; Lacroix C; Charlier G; Debecq J
    Arch Exp Veterinarmed; 1976; 30(3):325-31. PubMed ID: 185978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined method (suspension-monolayer) of preparing an inactivated foot-and-mouth disease vaccine].
    Genov I; Tivchev G; Veleva E; Tekerlekov P; Shopov I
    Vet Med Nauki; 1981; 18(5):57-63. PubMed ID: 6275604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative quantification of foot-and-mouth disease virus (146 S antigen) by sucrose and potassium-bromide density gradient centrifugation.
    Liebermann H; Hantschel H
    Arch Exp Veterinarmed; 1988 Jan; 42(1):65-70. PubMed ID: 2835937
    [No Abstract]   [Full Text] [Related]  

  • 19. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde.
    Barteling SJ; Cassim NI
    Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Testing the activity of anti-foot-and-mouth disease vaccine in cattle: quantitative methods of antigenic extinction].
    Terré J; Stellmann C; Brun A; Favre H; Fontaine J
    Dev Biol Stand; 1976; 35():357-67. PubMed ID: 198306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.